Purpose:　Human　mammaglobin　(hMAM)　is　a　breast　tissue-specific　marker　that　may　have　potency　for　the　diagnosis　of　breast　cancer.　However,　there　is　a　lack　of　commercialization　of　anti-hMAM　antibody　made　in　China.　Methods:　Immunoreactivities　of　2　self-made　monoclonal　anti-hMAM　antibodies,　MEF521　and　MDA822,　were　evaluated　by　immunohistochemistry　staining　and　compared　with　imported　monoclonal　antibody　ab81611.　A　total　of　48　cases　of　primary　breast　cancers,　36　cases　of　benign　or　normal　breast　tissues,　52　cases　of　lymph　nodes　or　organ　metastases　from　breast　cancer,　and　90　cases　of　non-breast　primary　carcinoma　tissues　were　analyzed.　Results:　All　3　anti-hMAM　antibodies　showed　high　positive　expression　of　hMAM　in　primary　breast　cancers,　benign,　and　normal　breast　tissues.　The　positive　ratio　for　MEF521　(33.3%)　or　MDA822　(44.4%)　was　much　higher　than　that　of　ab81611　(16.7%)　in　lymph　node　metastasis　from　breast　cancer　(p　=　0.038).　There　was　no　correlation　between　hMAM　expression　and　clinicopathologic　features　of　breast　cancer　in　the　3　groups　of　antibodies.　In　90　cases　of　non-breast　primary　carcinoma　tissues,　no　hMAM-positive　ones　were　observed　in　the　MEF521　or　MDA822　group,　but　48　(53.3%)　in　the　ab81611　group　were　positive,　indicating　that　breast　tissue　specificity　of　the　2　self-made　anti-hMAM　monoclonal　antibodies　much　higher　than　that　of　ab81611　(p＜0.001).　Conclusions:　Our　results　showed　that　MDA822　and　MEF521　are　more　specific　to　breast　cancer　as　measured　by　means　of　immunohistochemistry.　Therefore,　the　2　self-made　anti-hMAM　antibodies　may　have　good　prospects　for　clinical　application　in　the　differential　diagnosis　of　breast　tumor　and　breast　cancer　metastases.